Clinical Trial Update: Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) [Phase 2]

View source ↗

Summary

Phase 2a human challenge trial of MK-1654 (clesrovimab) in healthy participants has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Disease
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Clesrovimab (clesrovimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Respiratory Syncytial Viruses | Phase 2 | Status: COMPLETED | Results posted: 2021-04-13